S-Biotek   Report issue

For profit Phase 1
Founded: Copenhagen Denmark (2008)
Status: Acquired by Agilent Technologies, Inc. (2019)

Organization Overview

First Clinical Trial
2009
NCT01101633
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SBiotek

Active Ingredients

Drugs in Phase 1 Trials (1)

sodium alginate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Overweight (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1